GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

BACKGROUND: Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of different treatment approaches and regardless of the line of therapy. METHODS/DESIGN: GA101 (o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Trials
Main Authors: Oughton, Jamie B., Collett, Laura, Howard, Dena R., Hockaday, Anna, Munir, Talha, McMahon, Kathryn, McParland, Lucy, Dimbleby, Claire, Phillips, David, Rawstron, Andy C., Hillmen, Peter
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2017
Assuntos:
Study Protocol
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5530563/
https://ncbi.nlm.nih.gov/pubmed/28747208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-017-2107-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares